Sanofi India Q3 profit falls 8%; Rs 75 interim dividend declared

Revenue DeclineEbitda Margin ExpansionExceptional ItemResults View source PDF Explain this filing

SANOFI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.5%Reaction day

₹4751.00

prior close

₹4755.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.5%-1.0% vs market

Pharmaceuticals peers, median of 154sector+0.4%-0.9% vs sector

On the reaction day the stock moved 1.0 pts less than Nifty Microcap 250 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.8

15m

-0.7

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.5+0.5-1.0+0.4-0.9

Next day

+1.2+0.3+1.0+0.1+1.1

+0.8-0.1+0.9-0.3+1.1

+0.7+1.0-0.3+0.9-0.2

-0.0+0.2-0.2+0.0-0.0

+0.4-1.5+1.8-1.3+1.7

-3.4-1.5-1.9-2.0-1.4

15d

-3.9-1.7-2.2-2.8-1.1

-8.2-3.1-5.2-2.9-5.4

-14.1-6.6-7.5-5.6-8.5

-14.1-12.3-1.9-11.2-2.9

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 154Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sanofi India reported September-quarter revenue of Rs 4,754 crore, down 9% from Rs 5,240 crore, and profit after tax of Rs 760 crore, down 8% from Rs 822 crore. It recorded a Rs 273 crore exceptional charge. Nine-month continuing profit rose 19% to Rs 2,650 crore, while total profit fell 18% after the prior-year Consumer Healthcare business was classified as discontinued. The board declared a Rs 75 interim dividend, payable within 30 days.

Likely market impact

Lower quarterly sales and profit may weigh on the stock, but the interim dividend and cost control offer support. The exceptional charge is a concern.